1-isopentyl-4-methyl-pentylamine | 67232-55-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-isopentyl-4-methyl-pentylamine
• 英文别名: 1-Isopentyl-4-methyl-pentylamin；5-Amino-2.8-dimethyl-nonan；Diisopentylmethyl-amin；4-methyl-1-(3-methylbutyl)pentylamine；2,8-Dimethylnonan-5-amine
• CAS: 67232-55-7
• 化学式: C₁₁H₂₅N
• 分子量: 171.326
• InChiKey: AMQHYLOASSQYSW-UHFFFAOYSA-N

物化性质

• 沸点：
  213.6±8.0 °C(Predicted)
• 密度：
  0.797±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-isopentyl-4-methyl-pentylamine 、 1-isopentyl-4-methyl-pentyl isocyanate 生成 N,N'-bis-(1-isopentyl-4-methyl-pentyl)-urea
  参考文献：
  名称：

  Huang, Journal of the Chinese Chemical Society, 1948, vol. 15, p. 237

  摘要：

  DOI：
• 作为产物：
  描述：

  1-isopentyl-4-methyl-pentyl isocyanate 在 盐酸 作用下， 生成 1-isopentyl-4-methyl-pentylamine
  参考文献：
  名称：

  Huang, Journal of the Chinese Chemical Society, 1948, vol. 15, p. 237

  摘要：

  DOI：

文献信息

• Epoxysuccinic acid derivatives
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US05843992A1

  公开（公告）日：1998-12-01

  An epoxysuccinic acid derivative having the following formula: ##STR1## \x9bwherein R.sup.1 is hydrogen, alkyl, aryl, or aralkyl; each of R.sup.2 and R.sup.3 independently is aryl, aralkyl or alkyl; X is --O-- or --NR.sup.4 --; and R.sup.4 is hydrogen, alkyl, or aralkyl! is useful for prevention and treatment of bone diseases such as osteoporosis, malignant hypercalcemia and Paget's syndrome, and further useful for treatment of osteoarthritis and rheumatoid arthritis which are accompanied by abnormal enhancement of cathepsin L activity, and furthermore useful as a medicine for treating diseases in which cathepsin B and L participate, such as muscular dystrophy and muscular atrophy.

  具有以下式子的环氧琥珀酸衍生物：##STR1## 其中，R1为氢、烷基、芳基或芳基烷基；R2和R3各自独立地为芳基、芳基烷基或烷基；X为--O--或--NR4--；R4为氢、烷基或芳基烷基！可用于预防和治疗骨疾病，如骨质疏松症、恶性高钙血症和帕吉特综合症，并且可用于治疗伴随有猫hepsin L活性异常增强的骨关节炎和类风湿性关节炎，此外还可用作治疗猫hepsin B和L参与的疾病的药物，如肌营养不良和肌萎缩症。
• Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof
  申请人：Hardy Larry Wendell

  公开号：US20110319380A1

  公开（公告）日：2011-12-29

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中提供的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5(mGluR5)的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• Alkylenediamine derivatives
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：EP0235942A1

  公开（公告）日：1987-09-09

  Novel alkylenediamine derivative having the formula (I): wherein A is a group having the formula (II): (wherein R1 is an aliphatic hydrocarbon group, an alicyclic group, an aryl group, or an aralkyl group; R2 is an aliphatic hydrocarbon group, en alkoxy group, an aliphatic hydrocarbon group containing an ester or ether bonding, or an aryloxy group; and each of m and n is an integer of 0 to 2, provided that m + n does not exceed 3) and B is hoydrogen, or A is a group having the formula (III): (wherein R3 has the same meaning as that of R1 and k is an integer of 0 to 3) and B is a group repesenting by the formula (IV): wherein R4 has almost the same meaning as that of R2, p is an integer of 2 to 6, and q is an integer of 4 to 7. These compounds are useful as glutamate blockers.

  具有式（I）的新型烷基二胺衍生物： 其中 A 是具有式（II）的基团： (其中 R1 是脂族烃基、脂环族基团、芳基或芳烷基；R2 是脂族烃基、烯烷氧基、含有酯键或醚键的脂族烃基或芳氧基；且 m 和 n 均为 0 至 2 的整数，但 m + n 不超过 3），B 是氢，或 A 是具有式（III）的基团： (其中 R3 与 R1 意义相同，k 为 0 至 3 的整数），B 为式（IV）所示基团： 其中 R4 的含义与 R2 基本相同，p 是 2 至 6 的整数，q 是 4 至 7 的整数。 这些化合物可用作谷氨酸阻断剂。
• EPOXYSUCCINIC ACID DERIVATIVES
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：EP0826681A1

  公开（公告）日：1998-03-04

  Epoxysuccinic acid derivatives having general formula (I) (wherein R1 represents hydrogen, alkyl, aryl or aralkyl; R2 and R3 independently represent each aryl, aralkyl or alkyl; and X represents -O-or NR4- wherein R4 represents hydrogen, alkyl or aralkyl) which is useful in the prevention or treatment of bone diseases such as osteoporosis, malignant hypercalcemia, and bone Behcet's disease, in the treatment of osteoarthritis and rheumatoid arthritis in association with the abnormal hyperergasia of cathepsin L activity, and as a remedy for diseases in which cathepsins L and B participate such as muscular dystrophy and amyotrophy.

  具有通式(I)的环糊精酸衍生物（其中 R1 代表氢、烷基、芳基或芳烷基；R2 和 R3 分别独立地代表芳基、芳烷基或烷基；X代表-O-或NR4-，其中R4代表氢、烷基或芳烷基），可用于预防或治疗骨质疏松症、恶性高钙血症和骨白塞氏病等骨科疾病，治疗骨关节炎和类风湿性关节炎等与酪蛋白酶L活性异常亢进有关的疾病，以及治疗肌肉萎缩症和肌萎缩症等酪蛋白酶L和B参与的疾病。